{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Yttrium_Y-90_Epratuzumab_Tetraxetan",
  "nciThesaurus": {
    "casRegistry": "501423-25-2",
    "chebiId": "",
    "chemicalFormula": "C16H25N5O7.Y",
    "definition": "A radioimmunotherapeutic humanized murine monoclonal antibody (LL2) directed against the CD22 pan-B-cell antigen and chelated to the radioisotope yttrium-90 (Y 90). Y 90 humanized monoclonal antibody LL2 binds to tumor cells expressing CD22, delivering a cytotoxic dose of beta radiation.",
    "fdaUniiCode": "J36232195E",
    "identifier": "C2582",
    "preferredName": "Yttrium Y-90 Epratuzumab Tetraxetan",
    "semanticType": "Amino Acid, Peptide, or Protein",
    "subclassOf": [
      "C129819",
      "C1511"
    ],
    "synonyms": [
      "Monoclonal antibody LL2, yttrium Y 90",
      "Y 90 Humanized Monoclonal Antibody LL2",
      "Y 90 MoAb LL2",
      "Y 90 monoclonal antibody LL2",
      "Y90 Humanized Epratuzumab Tetraxetan",
      "YTTRIUM Y-90 EPRATUZUMAB TETRAXETAN",
      "Yttrium Y 90 Humanized Epratuzumab Tetraxetan",
      "Yttrium Y 90 Humanized Monoclonal Antibody LL2",
      "Yttrium Y-90 Epratuzumab Tetraxetan",
      "yttrium Y 90 MOAB LL2"
    ]
  }
}